Restrictions are provisional measures while review of liver safety is ongoing
The European Medicines Agency (EMA) is provisionally restricting the use of the multiple sclerosis medicine Zinbryta (daclizumab) to patients with highly active relapsing disease that has failed to respond to certain other treatment, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines.
More information:
